Suzanne Hancock
Chief Operating Officer bei RENEURON GROUP PLC
Ursprung des Netzwerks ersten Grades von Suzanne Hancock
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 21 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Suzanne Hancock
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Athena Neurosciences LLC
Athena Neurosciences LLC Miscellaneous Commercial ServicesCommercial Services Athena Neurosciences LLC operates as a research-based pharmaceutical company committed to the field of neurology. It develops therapeutic and diagnostic products. The company was founded by David Rowley-Jones, Larry C. Fritz, and Larry A. Bock in 1986 and is headquartered in Allegan, MI. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
UNILEVER PLC | Household/Personal Care | Corporate Officer/Principal | |
MedImmune Ltd.
MedImmune Ltd. BiotechnologyHealth Technology MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chief Executive Officer | |
Zeneus Pharma Ltd.
Zeneus Pharma Ltd. Medical DistributorsDistribution Services Zeneus Pharma Ltd. provides pharmaceutical products. It offers license to late-stage development, pre and post-approval, and marketing services across Europe for specialty hospital medicines. The company was founded in 2004 by Bryan Morton and is headquartered in Oxford, UK. | Medical Distributors | Chief Tech/Sci/R&D Officer | |
SAREUM HOLDINGS PLC | Miscellaneous | Chairman Director/Board Member | |
Antisoma Research Ltd. | Corporate Officer/Principal General Counsel | ||
TIGENIX NV | Medical Specialties | Director of Finance/CFO | |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Medical Specialties | Corporate Officer/Principal | |
OXFORD BIOMEDICA PLC | Biotechnology | Public Communications Contact | |
University of Oxford | College/University | Undergraduate Degree Undergraduate Degree | |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Imperial College London | College/University | Graduate Degree Undergraduate Degree | |
University of Cambridge | College/University | Undergraduate Degree Doctorate Degree | |
PHYSIOMICS PLC | Miscellaneous Commercial Services | Chairman Director/Board Member | |
University of London | College/University | Undergraduate Degree Graduate Degree | |
ReNeuron Ltd.
ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
WEIFA ASA | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer | |
University of Bocconi | College/University | Doctorate Degree | |
London Business School | College/University | Masters Business Admin Corporate Officer/Principal | |
Johnson & Johnson Ltd.
Johnson & Johnson Ltd. Household/Personal CareConsumer Non-Durables Part of Kenvue, Inc., Johnson & Johnson Ltd. is a British company that manufactures health care products. The private company is based in Maidenhead, UK. Founded in 1987. | Household/Personal Care | Chief Tech/Sci/R&D Officer | |
University of Hertfordshire | College/University | Undergraduate Degree | |
BANCO SANTANDER, S.A. | Major Banks | Corporate Officer/Principal | |
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director of Finance/CFO | |
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Private Equity Investor | |
Glaxo Group Research Ltd. | Corporate Officer/Principal | ||
The University of Law Ltd. | College/University | Graduate Degree | |
Food & Drug Analytical Services Ltd.
Food & Drug Analytical Services Ltd. Miscellaneous Commercial ServicesCommercial Services Food & Drug Analytical Services Ltd. provides pharmaceutical quality control testing services. Its services include raw material, product release, and stability testing, microbiology, and development services. The firm also offers analytical methodologies, ICH stability storage, development and validation services. The company was founded in 2004 and is headquartered in Nottingham, the United Kingdom. | Miscellaneous Commercial Services | Chairman | |
HRA Pharma Development SARL
HRA Pharma Development SARL Pharmaceuticals: MajorHealth Technology HRA Pharma Development SARL develops medicines and products for women's health and endocrinology. It offers emergency contraception, uterine fibroids, regular contraception, intimate health, genital herpes, and Lysosafe service. The company was founded by André Ulmann in 1996 and is headquartered in Châtillon, France. | Pharmaceuticals: Major | Director/Board Member | |
GlaxoSmithKline Services Unlimited
GlaxoSmithKline Services Unlimited Pharmaceuticals: MajorHealth Technology Glaxosmithkline Services Unlimited Ltd. develops, manufactures and markets pharmaceutical products. The company was incorporated on March 23, 1972 and is headquartered in Brentford, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
REDX PHARMA PLC | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
Therachon Holding GmbH
Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland. | Biotechnology | Director of Finance/CFO | |
Peel Hunt LLP
Peel Hunt LLP Investment Banks/BrokersFinance Peel Hunt LLP is an independent securities brokerage firm headquartered in London, UK. The firm was founded in 1989 as a market liquidity provider to retail and institutional investors. They provide bespoke dealing and execution services for institutional asset managers, registrars, private client wealth managers and private banks. | Investment Banks/Brokers | Sales & Marketing | |
BENEVOLENTAI | Biotechnology | Director of Finance/CFO | |
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Locate Bio Ltd.
Locate Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Locate Bio Ltd. operates as a regenerative medicine development company. The firm focuses on clinical problems in which regeneration of human tissue will displace biomaterial or drug therapies. Its products are orthopaedic matrices with unique properties for hard to heal clinical applications. The company was founded by Robin Quirk and is headquartered in Nottingham, the United Kingdom. | Miscellaneous Commercial Services | Chairman | |
Oval Medical Technologies Ltd.
Oval Medical Technologies Ltd. Medical SpecialtiesHealth Technology Oval Medical Technologies Ltd. manufactures drug delivery devices focusing on vials, prefilled syringes, and autoinjectors. It provides an environment for the storage of all drugs including fragile biologics. The company was founded by Matthew Young in 2009 and is headquartered in Cambridge, the United Kingdom. | Medical Specialties | Chairman |
Statistik
International
Vereinigtes Königreich | 31 |
Vereinigte Staaten | 5 |
Spanien | 4 |
Belgien | 3 |
Schweiz | 3 |
Sektoral
Health Technology | 20 |
Consumer Services | 9 |
Commercial Services | 8 |
Finance | 6 |
Consumer Non-Durables | 3 |
Operativ
Director/Board Member | 114 |
Corporate Officer/Principal | 51 |
Chairman | 50 |
Independent Dir/Board Member | 28 |
Chief Tech/Sci/R&D Officer | 21 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Iain Ross | 41 |
Simon Cartmell | 39 |
John Berriman | 24 |
Paul Harper | 20 |
Timothy Corn | 20 |
Michael Owen | 20 |
Martin Walton | 16 |
Olav Hellebø | 13 |
Claudia D'Augusta | 12 |
Richard Beckman | 12 |
Barbara Staehelin | 10 |
Michael Elliot Hunt | 8 |
Nicholas Adams | 7 |
Sharon Grimster | 6 |
Simon Dew | 6 |
- Börse
- Insiders
- Suzanne Hancock
- Unternehmensverbindungen